Novavax says partners got Nuvaxovid formulation approval

Novavax Inc. announced that its partners have received regulatory approval for the updated formulation of its Nuvaxovid™ COVID-19 vaccine, designed for the 2025–2026 season. The approval marks a key milestone in the company’s strategy to provide a protein-based alternative to mRNA vaccines in the ongoing global pandemic response.

The Nuvaxovid vaccine, which utilizes a recombinant nanoparticle technology combined with Matrix-M™ adjuvant, has demonstrated strong safety and efficacy profiles in clinical trials. The updated formulation reflects adjustments to match the circulating variants of the virus, ensuring continued relevance in public health strategies.

This development is expected to support Novavax’s commercial operations and partnerships, particularly in regions where non-mRNA vaccine options are in demand. Investors may view the approval as a positive step toward expanding the company’s market reach and reinforcing its role in the global vaccine landscape.